A5049349649- Health Systems, Economic Evaluations, Quality of Life
- Atrial Fibrillation Management and Outcomes
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Health and Medical Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Dermatology and Skin Diseases
- Clinical practice guidelines implementation
- Pharmaceutical Economics and Policy
- Food Allergy and Anaphylaxis Research
- Cardiac pacing and defibrillation studies
- Coronary Interventions and Diagnostics
- Acute Ischemic Stroke Management
- Respiratory and Cough-Related Research
- Total Knee Arthroplasty Outcomes
- Inhalation and Respiratory Drug Delivery
- Acute Myocardial Infarction Research
- Heart Failure Treatment and Management
- Cardiovascular Syncope and Autonomic Disorders
- Healthcare cost, quality, practices
- Pancreatic and Hepatic Oncology Research
- Migraine and Headache Studies
- Peripheral Artery Disease Management
Medizinische Hochschule Hannover
2020-2025
IQVIA (United Kingdom)
2023
Steinbeis University Berlin
2012-2022
DIAKO
2021
Charité - Universitätsmedizin Berlin
2007-2018
Siemens Healthcare (Germany)
2017
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2016
Institute of Pathology Celle
2006-2011
Institute for Health Economics and Policy
2010
University Medical Center
2010
Abstract Background The German Therapy Allergen Ordinance (TAO) triggered an ongoing upheaval in the market for house dust mite (HDM) allergen immunotherapy (AIT) products. Three HDM subcutaneous AIT (SCIT) products hold approval Germany and therefore will be available after scheduled completion of TAO procedure 2026. In general, data from clinical trials on long‐term effectiveness are rare. We evaluated real‐world (RWD) a retrospective, observational cohort study based longitudinal claims...
Abstract Background The objective of this study was to analyze the effectiveness allergen immunotherapy (AIT) with an allergoid in treatment house dust mites (HDM)‐induced allergic rhinitis and/or asthma based on recent real‐life data. outcomes were measured using incidence and consumption corresponding medications as indicator persisting symptoms. Methods In retrospective cohort analysis a German longitudinal prescription database, patients who received at least two relevant mite AIT...
Allergen immunotherapy (AIT), when continued for 3 years, is the only disease-modifying treatment AR and asthma. Adherence a key to ensure effectiveness, poor adherence contraindication AIT. The objective of this study was evaluate real-world AIT with subcutaneous (SCIT) sublingual (SLIT) preparations in patients allergic grass or tree pollen. impact on consumption asthma rhinitis medication also analyzed.In retrospective cohort analysis German longitudinal prescription database, pollen...
Mit dem Wettbewerbsstärkungsgesetz von April 2007 kann das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) vom Gemeinsamen Bundesausschuss (G-BA) mit der Kosten-Nutzen-Bewertung Arzneimitteln beauftragt werden. Im Januar 2008 hat IQWiG in einem ersten Methodenvorschlag dargelegt, wie es die zukünftig durchzuführen gedenkt. In vorliegenden Stellungnahme AG Methoden gesundheitsökonomischen Evaluation (AG MEG) wird des kritisch bewertet Empfehlungen eine...
Pancreatic cancer is an aggressive with low survival time, health-related quality of life (HRQoL) being major importance. The aim our study was to assess both generic and disease-specific HRQoL in patients pancreatic cancer.Patients were consecutively included at admission hospital. determined the European Organization for Research Treatment Cancer (EORTC) EuroQoL (EQ-5D) health status instruments. Scores compared those norm populations. association symptoms overall analysed using linear...
Das Deutsche Netzwerk Versorgungsforschung e. V. (DNVF V.) hat am 1. Juli 2009 getragen von den genannten im DNVF organisierten Fachgesellschaften und Organisationen, ein Memorandum III "Methoden für die Versorgungsforschung" Teil 1 verabschiedet, das in dieser Zeitschrift publiziert wurde [Gesundheitswesen 2009; 71: 505–510]. Die vorliegende Publikation stellt eine Vertiefung zu Epidemiologischen Methoden der dar. Gesetzliche, politische ökonomische Eingriffe medizinische Versorgungssystem...
The purpose of this study was to determine the 12 months medical resource use following admission hospital with acute stroke and calculate costs from a societal perspective. Data consecutive patients confirmed were analysed. Acute data taken records, socio‐demographic variables patients’ interviews. A follow‐up questionnaire about utilization completed by or proxies after admission. Costs calculated multiplying units used cost factors per unit. Mean age total 383 65 years 41% female. median...
Since atrial fibrillation (AFib) is one of the most frequent cardiac disorders, primary aim present study was to assess disease-related costs as well course associated with AFib. The focused on a hospitalized patient subgroup comorbidities.We undertook retrospective review medical, hospital, and drug claims data in database German statutory health insurance company covering ∼5 million insured persons. patients suffering from AFib were extracted by using documented hospital International...
Das Deutsche Netzwerk Versorgungsforschung e. V. (DNVF V.) hat am 30.08.2010 getragen von den genannten im DNVF organisierten Fachgesellschaften und Organisationen, das Memorandum III "Methoden für die Versorgungsforschung" Teil 2 verabschiedet, in dieser Zeitschrift publiziert wurde [Gesundheitswesen 2010; 72: 739–748]. Die vorliegende Publikation fokussiert auf Methodik der ökonomischen Evaluation Gesundheitstechnologien bzw. Interventionen stellt eine Vertiefung zu dem dar. Zunächst...
The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) clinical practice are not well understood. ETNA-VTE Europe is a prospective, noninterventional, post-authorization study unselected VTE treated edoxaban eight European countries for up 18 months. Recurrent VTE, major bleeding, all-cause death were primary outcomes. median age 2,644 was 65 years; 46.6% female, 22.8% had history VTE. duration 50.6 weeks...
Abstract Background Low-dose direct oral anticoagulants (DOACs) are indicated to mitigate bleeding risk during thromboprophylaxis for certain patients with atrial fibrillation (AF). No randomised clinical trials have directly compared outcomes low-dose edoxaban vs apixaban; thus, assessing these treatments in routine practice is important informing patient management this setting. Purpose With strong evidence the overall benefit of (the most recently approved DOAC Italy), we aimed evaluate...
SUMMARYBackground: Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with budesonide/formoterol could maintain health-related quality of life (HRQL) and asthma control.Patients/methods: Asthma patients (n = 4025) received (Symbicort* 160/4.5 µg) 2 inhalations twice daily (bid) 4 weeks during run-in this open, multicentre study. Patients were randomised to (budesonide/formoterol 1 inhalation bid; stepping up or...